IP Library Granted Patent US 8,852,614
Granted Patent B2
US 8,852,614 · App. 13/065,030 · Granted Oct 7, 2014

Hydrogels with network defects enhanced by nanoparticle incorporation

Inventors: Curtis W. Frank (Cupertino, CA); Won Jae Lee (Mountain View, CA); Nam-Joon Cho (Stanford, CA); Jeffrey S. Glenn (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
B82Y5/00C12N5/0671A61K35/12A61K9/5184C12N2533/30A61K38/00C12N2533/40Y10S977/773Y10S977/915Y10S977/923
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,852,614
App. No.
13/065,030
Granted
Oct 7, 2014
Kind
B2
Abstract

Compositions and methods are provided for the manufacture and use of hydrogels with increased permeability to macromolecules with minimum loss of matrix mechanical strength and prepolymer viscosity for patternability. The hydrogels of the invention are formed from a prepolymer, which is polymerized in the presence of hydrophobic nanoparticles. In some embodiments of the invention cells are present during polymerization, and are encapsulated by the hydrogel. A high interfacial energy between the hydrophobic substrate and the aqueous polymerizing solution disrupts the hydrogel network structure, leading to network defects that increase permeability without loss of patternability.

Claims (14)

1. A cellular composition comprising:

viable liver cells encapsulated in a high permeability hydrogel with network defects resulting from introduction of hydrophobic nanoparticles;

wherein the composition is formed by combining in a precursor solution polyethylene glycol (PEG) diacrylate with poly(lactic-co-glycolic acid) (PLGA) nanoparticles, in the presence of viable liver cells and a polymerization initiator,

wherein the diameter of the nanoparticles is from about 100 nm to about 100 μm diameter; and

wherein the concentration of the nanoparticles is from 0.01% to 1% weight/volume of the precursor solution.

2. The composition of claim 1 , wherein the hydrogel comprises biologically active peptides or proteins.

3. The composition according to claim 2 , wherein the biologically active peptides or proteins are linked to PEG.

4. The composition of claim 1 , wherein the viable liver cells are primary cells.

5. The composition according to claim 1 , wherein the hydrogel is patterned into a nanostructure prior to polymerization.

6. The composition of claim 1 , wherein the polymerization initiator is a photoinitiator.

7. A pharmaceutical formulation comprising a composition according to claim 1 ; and

a pharmaceutically acceptable excipient.

8. The cellular composition of claim 1 , wherein the PEG diacrylate has a molecular weight of at least 2.5 K and not more than 20 K.

9. The cellular composition of claim 1 , wherein the PEG diacrylate is present in the precursor solution at a concentration of at least 7.5% and not more than 30%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2011
From: FRANK, CURTIS W.; LEE, WON JAE; CHO, NAM-JOON; GLENN, JEFFREY S.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 026537/0451 →
Continuity (2)
Provisional Application 61340117 · Mar 12, 2010
Related Publication 20110256183A1 · Oct 20, 2011